Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMEA Ventures Into Development, But Not Tied To Lilly As Expected

Executive Summary

Several biopharma venture investors are experimenting with new models to avoid the long timelines and massive pay checks typically required to nurture new biotech companies. One of those investors, CMEA Capital of San Francisco, officially debuted its model Thursday, June 23, but not before making a major strategic shift.

You may also be interested in...



With Partner Lilly, TVM Capital Gets A Canadian Makeover

One of two venture firms signed up to run an Eli Lilly “mirror portfolio” of single-asset companies, venerable TVM Capital has made significant changes to get its new model off the ground.

Financings Of The Fortnight: VCs Not Wowed By Single-Asset Company Model

Venture capitalists tell START-UP’s annual survey that seeing will be believing when it comes to the potential of single-asset models. Plus news on recent financings by iPierian, Evotec, ObsEva and Acacia.

Financings Of The Fortnight: Life Science Venture Funding Not Necessarily On The Decline

Plus news on recent financings by Foundation Medicine, Ultragenyx, Labrys Biologics, Solstice Biologics and Sarepta Therapeutics.

Related Content

Topics

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel